Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Friday, December 8, 2023 | Back issues
Courthouse News Service Courthouse News Service

Big Pharma

MANHATTAN - A class of health insurance plans claiming that Sanofi-Aventis underplayed safety risks associated with the antibiotic Ketek cannot proceed as a class, the Second Circuit affirmed Friday.

Categories / Uncategorized

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.